Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the ...

Biopharmaceutical firm Hutchmed China Ltd., backed by billionaire Li Ka-shing, has agreed to sell stakes in a health unit for ...

Hutchmed, a biopharmaceutical company controlled by Hong Kong’s wealthiest person Li Ka-shing, is divesting a 45% stake in a ...

HUTCHMED (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around US$608 million as ...

Li Ka-shing’s flagship developer has priced the first batch of flats at an average of HK$21,526 per square foot, below the HK$28,000 development cost.

Low prices will persist as developers offload inventory, but the market will fail to woo investors, according to experts.

Jan 1 (Reuters) - Hutchmed (China)(0013.HK), opens new tab, controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the billionaire and his flagship ...

The biopharmaceutical firm is set to divest shares in a joint venture to focus on its core business of developing novel ...

Li Ka Shing, whose net worth approaches US$36 billion and who is often dubbed the “Warren Buffett of Asia,” was recently seen wearing an Apple Watch on his wrist. Hong Kong billionaire Li Ka ...

The Li Ka-shing Center for Biomedical and Health Sciences will make a huge contribution to the advancement of medical research. The facility houses computer scientists, biologists, physicists, ...

Shareholding disclosures revealed that from the 17th to the 20th of this month, the Li Ka Shing Foundation invested nearly ...